Modality
siRNA
MOA
BiTE
Target
JAK2
Pathway
Apoptosis
PTSD
Development Pipeline
Preclinical
Jul 2022
→ Aug 2027
PreclinicalCurrent
NCT06742481
642 pts·PTSD
2022-07→2027-08·Not yet recruiting
642 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-238mo awayFast Track· PTSD
2027-08-121.4y awayInterim· PTSD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Preclinical
Not yet…
Catalysts
Fast Track
2026-11-23 · 8mo away
PTSD
Interim
2027-08-12 · 1.4y away
PTSD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06742481 | Preclinical | PTSD | Not yet recr... | 642 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |